All News
Filter News
Found 808,679 articles
-
Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential
10/4/2022
Dyadic International, Inc. announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccine Congress in Barcelona, Spain.
-
Ampio Pharmaceuticals Issues Letter to Stockholders - October 04, 2022
10/4/2022
Ampio Pharmaceuticals, Inc., released the following letter to stockholders from its Chairman, Kevin Buchi, and Chief Executive Officer, Mike Martino.
-
Myrtelle Completes Dosing of 8 Patients with Canavan Disease in Its Phase 1/2 Clinical Trial of the Investigational Gene Therapy rAAV-Olig001-ASPA
10/4/2022
Myrtelle Inc., a gene therapy company focused on developing transformative treatments for neurodegenerative diseases, announced the completion of dosing of 8 patients with the Company’s recombinant adeno-associated virus vector-based investigational gene therapy for Canavan disease.
-
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
10/4/2022
Immunovant, Inc., a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at an offering price of $6.00 per share.
-
Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer
10/4/2022
Immutep Limited announced the United States Food and Drug Administration has granted Fast Track designation to eftilagimod alpha in combination with pembrolizumab for the treatment of 1st line non-small cell lung cancer.
-
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2022 on Monday, October 31, 2022
10/4/2022
Hologic, Inc. announced that the Company plans to release its financial results for the fourth quarter of fiscal 2022 on Monday, October 31, after the market closes.
-
Santa Monica Businesses Welcome German Health Trade and Science Delegation
10/4/2022
Quantgene, a Santa Monica, California, and Berlin, Germany-based biotechnology, cloud and artificial intelligence company, will host a delegation of healthcare executives and scientific leaders from Baden-Württemberg at its headquarters on October 5.
-
Helixmith to Present New ALS-Focused Development Program at Upcoming Conferences
10/4/2022
Helixmith announced that their CEO, Dr. Sunyoung Kim, will be presenting an overview of their ALS-focused program, named DART, Defeating ALS through Regenerative Therapeutics, at both the 2022 Cell & Gene Meeting on the Mesa and the 2022 BIO-Europe Conference.
-
SyntheX and Bristol Myers Squibb Enter Into a Research Collaboration to Discover and Develop Targeted Protein Degradation (TPD) Therapeutics
10/4/2022
SyntheX, Inc., an emerging growth biotechnology company innovating next-generation functional drug discovery engines, announced a research collaboration and license agreement with Bristol Myers Squibb to discover, develop and commercialize novel small molecules using SyntheX's ToRNeDO platform for protein degradation.
-
Daxor Corporation to Exhibit and Present at the Medaxiom Cardiovascular Transforum Conference Fall’22 to Advance Awareness and Further Adoption of Daxor’s Blood Volume Diagnostic (BVA-100®)
10/4/2022
Daxor Corporation, the global leader in blood volume measurement technology, announces it will be exhibiting for the first time at the MedAxiom CV Transforum Fall’22 Conference being held at the JW Marriott in Austin, TX from October 6-8, 2022.
-
Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
10/4/2022
Cue Biopharma, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to CUE-101, its lead clinical drug candidate from the CUE-100 series of interleukin 2 -based biologics, for the treatment of patients with human papilloma virus recurrent/metastatic head and neck squamous cell carcinoma as a monotherapy and in combination with pembrolizumab.
-
TrialSpark announces partnership with major pharmaceutical company to jointly acquire and develop clinical-stage novel therapies
10/4/2022
TrialSpark announced a new partnership with global pharmaceutical company Sanofi to explore novel methods of bringing new treatments to patients faster and more efficiently.
-
Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer
10/4/2022
Personalis, Inc. has joined with Duke University and Olink Proteomics AB to form a research collaboration to study the effects of immunotherapy on advanced gastroesophageal cancer.
-
Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer
10/4/2022
Exagen Inc. announced the appointment of Andrew L. Concoff M.D. FACR, CAQSM as Chief Innovation Officer.
-
Kane Biotech Receives an Additional $425K USD of Funding for its DispersinB® Hydrogel from the United States Department of Defense DispersinB® Hydrogel Clinical trials to commence in 2022
10/4/2022
Kane Biotech Inc. announces that it has received an additional $425,000 USD of funding for its DispersinB Hydrogel® related to its Medical Technology Enterprise Consortium Research Project Award which was granted in 2020 and funded by the U.S. Department of Defense.
-
InterVenn Biosciences Expands Board of Directors with Dr. Jason Myers and Carol Berry to Support Next Phase of Growth
10/4/2022
InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, announced the appointment of Jason Myers, Ph.D., and Carol Berry to the company’s Board of Directors.
-
Catheter Precision Files a Method-of-Use U.S. Patent Application for its VIVO™ Technology
10/4/2022
Catheter Precision, Inc., a medical device company focused on cardiac electrophysiology, announces the filing of a new U.S. patent application for its VIVO™ technology, as it continues its focus on patent protection for VIVO.
-
HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner
10/4/2022
HanAll Biopharma, a global biopharmaceutical company developing innovative medicine, clarified that the new FcRn inhibitor HL161ANS, unveiled by its licensed partner Immunovant as a new development program, is a compound discovered and developed by HanAll.
-
Fresenius Kabi Expands Contrast Agent Portfolio with Launch of Gadoterate Meglumine Injection, USP
10/4/2022
Fresenius Kabi announced it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent Dotarem®.
-
RSIP Vision Presents New Urological AI Tool for 3D Reconstruction of the Ureter Improving Urological Procedures
10/4/2022
RSIP Vision, a leader in driving innovation for medical imaging through advanced AI and computer vision solutions, announces a new tool for 3D reconstruction of the ureter.